Unknown

Dataset Information

0

Response to MEK inhibition with trametinib and tyrosine kinase inhibition with imatinib in multifocal histiocytic sarcoma.

ABSTRACT:

SUBMITTER: Voruz S 

PROVIDER: S-EPMC5777214 | biostudies-literature | 2018 Jan

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Response to MEK inhibition with trametinib and tyrosine kinase inhibition with imatinib in multifocal histiocytic sarcoma.

Voruz Sophie S   Cairoli Anne A   Naveiras Olaia O   de Leval Laurence L   Missiaglia Edoardo E   Homicsko Krisztian K   Michielin Olivier O   Blum Sabine S  

Haematologica 20171102 1

Similar Datasets

Unknown Comment on "MEK inhibition with trametinib and tyrosine kinase inhibition with imatinib in multifocal histiocytic sarcoma".
| S-EPMC5830398 | biostudies-literature
Unknown MEK inhibition enhances the response to tyrosine kinase inhibitors in acute myeloid leukemia.
| S-EPMC6901485 | biostudies-literature
Unknown Efficacy of MEK inhibition in patients with histiocytic neoplasms.
| S-EPMC6438729 | biostudies-literature
Unknown The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma.
| S-EPMC5520097 | biostudies-literature
Unknown MEK inhibition with trametinib is a successful therapy in ganglioglioma.
| S-EPMC7523693 | biostudies-literature
Unknown Inhibition of an Erythrocyte Tyrosine Kinase with Imatinib Prevents Plasmodium falciparum Egress and Terminates Parasitemia.
| S-EPMC5074466 | biostudies-literature
Unknown Tyrosine kinase inhibitors in sarcoma treatment.
| S-EPMC9073578 | biostudies-literature
Unknown CIC-Mediated Modulation of MAPK Signaling Opposes Receptor Tyrosine Kinase Inhibitor Response in Kinase-Addicted Sarcoma.
| S-EPMC8930606 | biostudies-literature
Unknown Transcriptomic Alterations of Canine Histiocytic Sarcoma Cells in Response to Different Stressors
| S-EPMC12294338 | biostudies-literature
Unknown Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer.
| S-EPMC4669588 | biostudies-literature